ADX 10059

Drug Profile

ADX 10059

Alternative Names: ADX-10059

Latest Information Update: 18 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Addex Pharmaceuticals
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Drug-induced dyskinesia; Gastro-oesophageal reflux; Migraine; Parkinson's disease

Most Recent Events

  • 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in European Union (PO)
  • 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in USA (PO)
  • 15 Dec 2009 Discontinued - Phase-II for Migraine in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top